Finance Watch: $320m In New VC Deals Includes $110m Round For Neogene
Also, Recursion Raises $239m, Including $50m From New Partner Bayer
Private Company Edition: Neogene, Escient, ESCAPE, Resolution and Attralus raised a combined $320m in venture capital rounds. Also, large Recursion round could double the size of its pipeline, Korro Bio raised $91.5m and Flagship launched Generate Biomedicines.
You may also be interested in...
The company intends to use the series B cash to bring the first of its pan-amyloid removal (PAR) therapies into the clinic, while also advancing a diagnostic tool for systemic amyloidosis.
Building on 20 years of work and positive preclinical data, and backed by a fresh injection of cash, Alentis is taking its liver fibrosis candidate into Phase I trials in the fourth quarter.
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.